Article FDA Thank You The next chapter in the ctDNA story: Still promising, not ready for prime time
Agency IQ
JULY 21, 2023
The assessment of this benefit typically relies upon the use of specific endpoints to measure this clinical benefit, generally within the context of a clinical trial. [ OS is an outcome-related endpoint that is defined as the time from trial randomization until death from any cause in the intent-to-treat population.
40 
Let's personalize your content